AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22324939
Drug: Calcium montmorillonite
RxNorm normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium montmorillonite (NovaSil, NS) at a dosage of 3 g day⁻¹ for 3 months
Trial: 22324939
Drug: Calcium montmorillonite
RxNorm normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium montmorillonite (NovaSil, NS) at a dosage of 1.5 g day⁻¹ for 3 months
Trial: 20669673
Drug: Tongxinluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo Capsule (TXLC)
Trial: 16701189
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (Group I)
Trial: 16701189
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg intravenous magnesium (Group II)
Trial: 16701189
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg magnesium added to local anesthetic (Group III)
Trial: 16701189
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg magnesium added to local anesthetic (Group IV)
Trial: 4051211
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone (1.4 mg)
Trial: 29788982
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave lithotripsy (ESWL) as the first treatment option
Trial: 29788982
Drug: Ureteroscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ureteroscopic treatment
Trial: 23194481
Drug: Otamixaban (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otamixaban (0.08 mg/kg intravenous bolus at randomization then 0.100 or 0.140 mg/kg per hour intravenous infusion)
Trial: 18609695
Drug: Radiotherapy (irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (irradiation dose of 20 Gy/10 f/12 d, 40 Gy/20 f/24 d, and 60 Gy/30 f/36 d)
Trial: 16117982
Drug: Prescript-Assist (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescript-Assist (500 mg capsule BID)
Trial: 12049852
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg/d) during 6 weeks after delivery
Trial: 8648369
Drug: Epirubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 40 mg/m2
Trial: 8648369
Drug: Epirubicin 135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 135 mg/m2
Trial: 6751833
Drug: 750 ml
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 ml spacer
Trial: 24337079
Drug: BMS-820836 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-820836 0.5 mg
Trial: 24337079
Drug: BMS-820836 3
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-820836 3 mg
Trial: 24337079
Drug: BMS-820836 (0.025-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-820836 (0.025-3 mg)
Trial: 22672253
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to the GP requesting treatment according to NICE's 'stepped care' recommendations
Trial: 8593013
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg orally every 12 h for five doses
Trial: 8593013
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg orally every 24 h for three doses
Trial: 2503289
Drug: Daily bicycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bicycle exercise at 75 W for 1 hour during IVF
Trial: 2503289
Drug: IVF without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVF without daily exercise
Trial: 31030165
Drug: Pinitol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinitol (300 mg/d)
Trial: 31030165
Drug: Pinitol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinitol (500 mg/d)
Trial: 25876832
Drug: CR nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR nifedipine (80 mg per day; 40 mg BID)
Trial: 25885986
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 300 mcg
Trial: 25885986
Drug: Oral metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoprolol 50 mg
Trial: 17225162
Drug: AZD3480 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 (50 mg, 100 mg, 200 mg)
Trial: 17225162
Drug: AZD3480 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 (single dose from 2 to 320 mg)
Trial: 17225162
Drug: AZD3480 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 (50 mg, 200 mg)
Trial: 17225162
Drug: AZD3480 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 (200 mg)
Trial: 11472614
Drug: GM‐CSF impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF impregnated gauze (40 micrcog/cm2 of skin‐irradiated area, twice per day) in addition to steroid cream
Trial: 11472614
Drug: Steroid cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid cream
Trial: 3126635
Drug: Deponit 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deponit 10 patch (10 mg of nitroglycerin over 24 hours)
Trial: 3126635
Drug: Deponit 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deponit 10 patch
Trial: 27602880
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) consisting of 12 individual 1-hour sessions administered weekly by trained clinicians
Trial: 19907724
Drug: Hydroxyapatite (HA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite (HA) treatment
Trial: 15864232
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy during index hospitalization
Trial: 15864232
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering therapy during index hospitalization
Trial: 15864232
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with prior history of hyperlipidemia not discharged on lipid-lowering therapy
Trial: 15864232
Drug: Inpatient lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient lipid-lowering therapy
Trial: 14578647
Drug: Chemotherapy agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agents (e.g., fluorouracil, gemcitabine, taxanes, capecitabine)
Trial: 11275925
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abciximab and reduced-dose thrombolytic agent) with adjunctive PCI
Trial: 11275925
Drug: Full-dose thrombolytic
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose thrombolytic agent alone with adjunctive PCI
Trial: 11275925
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abciximab) with adjunctive PCI
Trial: 11275925
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (abciximab) without adjunctive PCI
Trial: 11275925
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy alone with adjunctive PCI
Trial: 11275925
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy alone without adjunctive PCI
Trial: 9249638
Drug: Polylactic-acid-based bioabsorbable
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polylactic-acid-based bioabsorbable barrier (test treatment)
Trial: 9249638
Drug: Non-absorbable ePTFE
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-absorbable ePTFE barrier (control treatment)
Trial: 21070344
Drug: Programme-assessed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programme-assessed treatment (elaborate feedback)
Trial: 21070344
Drug: Student-assessed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Student-assessed treatment (minimal feedback)
Trial: 16761129
Drug: d,l-methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-methamphetamine
Trial: 14586363
Drug: Desmopressin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.1 mg, 0.2 mg, or 0.4 mg)
Trial: 8937366
Drug: Penthienate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penthienate (5 mg, three times a day for 4 weeks)
Trial: 8937366
Drug: Propantheline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propantheline (15 mg, three times a day for 4 weeks)
Trial: 24688087
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m²)
Trial: 8590507
Drug: Diazepam 0.4
RxNorm normalized name: diazepam 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.4 mg.kg‐1
Trial: 8311533
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with steroids
Trial: 22341744
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care
Trial: 16942452
Drug: Mime therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mime therapy for three months (including massage, relaxation, inhibition of synkinesis, and coordination and emotional expression exercises)
Trial: 16942452
Drug: Mime therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mime therapy for three months
Trial: 10735462
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with albumin 20% 15 ml/kg
Trial: 1392423
Drug: Intravenous ANF(99‐126)
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ANF(99‐126) (bolus 100 micrograms/kg, 30‐min infusion of 0.1 micrograms/kg.min)
Trial: 1392423
Drug: Combined releasing
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined releasing hormone administration
Trial: 3904233
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily for 2 years
Trial: 2858709
Drug: Untreated control
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated control group with systemic therapy reserved until the time of relapse
Trial: 17167974
Drug: Splenectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Splenectomy without immunotherapy (OK-432 administration)
Trial: 17167974
Drug: Splenectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splenectomy with immunotherapy
Trial: 17167974
Drug: Spleen preservation
RxNorm normalized name: Bos taurus spleen preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen preservation without immunotherapy
Trial: 17167974
Drug: Spleen preservation
RxNorm normalized name: Bos taurus spleen preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen preservation with immunotherapy
Trial: 12860257
Drug: CETi‐1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETi‐1 vaccine (250 mg)
Trial: 12860257
Drug: CETi‐1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETi‐1 vaccine (second injection)
Trial: 12860257
Drug: CETi‐1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETi‐1 vaccine
Trial: 9350242
Drug: MMC +
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC + HCFU (intravenous MMC 6 mg/m2 on the day of operation followed by oral HCFU for 12 months from 2 weeks after operation)
Trial: 8478958
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of ethanol (approximately two average drinks) per day for three menstrual cycles
Trial: 3533551
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of controlled release theophylline (Uniphyllin)
Trial: 3533551
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of controlled release theophylline (Uniphyllin)
Trial: 3533551
Drug: Control (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (morning vs evening administration)
Trial: 26251065
Drug: Work-focused cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-focused cognitive-behavioural therapy (CBT) and individual job support
Trial: 23290982
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of zoledronate 5 mg
Trial: 21303636
Drug: Differentiated SoloSTAR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differentiated SoloSTAR® pens (insulin glargine vs insulin glulisine)
Trial: 21303636
Drug: FlexPen® (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FlexPen® (insulin detemir vs insulin aspart)
Trial: 19577022
Drug: Sham (placebo)
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (placebo) treatment 2 hours/day for 3 months
Trial: 16455169
Drug: Third-generation hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation hepatitis B vaccine containing PreS1 and PreS2 antigens in addition to the S antigen
Trial: 16455169
Drug: Conventional hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hepatitis B vaccine
Trial: 11704163
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of metronidazole gel intravaginally
Trial: 3126085
Drug: Superselective intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Superselective intra-arterial chemotherapy with mitomycin C (SIAC)
Trial: 3126085
Drug: Chemotherapy toxicity
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy toxicity after SIAC
Trial: 19001531
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (intervention group)
Trial: 25748415
Drug: Amoxicillin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (two 500 mg tablets three times a day for 7 days)
Trial: 24160442
Drug: Systematic CVD
RxNorm normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic CVD risk reduction package including healthy lifestyle counseling, prescription of a combination of drugs (antihypertensives, aspirin, and statin), and adherence support.
Trial: 1303480
Drug: Propofol 2.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.04 mg/kg
Trial: 1303480
Drug: Methohexitone 1.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 1.05 mg/kg
Trial: 6099756
Drug: Cefotaxime (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (multiple doses)
Trial: 14675576
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Trial: 14675576
Drug: Simvastatin monotherapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Trial: 11170979
Drug: Potent antiretroviral
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent antiretroviral therapy including ritonavir and saquinavir
Trial: 3202339
Drug: Spinal anaesthetic
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthetic with 1.5 mg.kg‐1 prilocaine (RA)
Trial: 3202339
Drug: General anaesthetic
RxNorm normalized name: General anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthetic with 5 mg.kg‐1 thiopentone, dextromoramide, nitrous oxide and enflurane (GA)
Trial: 30175930
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg plus chlorthalidone
Trial: 30175930
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg plus chlorthalidone
Trial: 24447649
Drug: Rasagiline 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline 6 mg/day
Trial: 1584429
Drug: Selegiline monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline monotherapy
Trial: 1750727
Drug: terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 60 mg b.i.d.
Trial: 1750727
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg b.i.d.
Trial: 6751366
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline 350 mg daily for 4 days followed by 700 mg daily for 4 days
Trial: 6751366
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for 8 days
Trial: 30509740
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks intravenously
Trial: 29282470
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (10 daily 30-minute, 2-mA sessions)
Trial: 26740484
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen therapy
Trial: 24488324
Drug: Icotinib 400
RxNorm normalized name: inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icotinib 400 mg with high-fat and high-calorie meal
Trial: 24488324
Drug: Icotinib (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (dose range 100-600 mg)
Trial: 22156624
Drug: EP/XRT (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP/XRT (cisplatin and etoposide with concurrent chest radiation)
Trial: 11986603
Drug: Non-heparin-bonded circuits
RxNorm normalized name: SKIN BOND NON-FLAMMABLE CEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-bonded circuits with cardiotomy suction (group I)
Trial: 11986603
Drug: Heparin-bonded circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded circuits with cardiotomy suction (group II)
Trial: 11986603
Drug: Heparin-bonded circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded circuits without cardiotomy suction (group III)
Trial: 9706319
Drug: Social-cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social-cognitive group intervention (ten, 2-hour weekly sessions)
Trial: 9706319
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of drug/alcohol users and nonusers, fighters and nonfighters, and students threatened at school and those not threatened
Trial: 7618676
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg by bolus injection followed by infusion (5 mg.h‐1 for 12 h and 2.5 mg.h‐1 for a further 12 h)
Trial: 7618676
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg by bolus injection followed by infusion (10 mg.h‐1 for 12 h and 5 mg.h‐1 for a further 12 h)
Trial: 7618676
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate 2 mg by bolus injection followed by infusion (0.2 mg.h‐1 for 12 h and at 0.1 mg.h‐1 for further 12 h)
Trial: 28750828
Drug: Alirocumab (75/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75/150 mg every 2 weeks)
Trial: 26712972
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg (Group O, n = 32)
Trial: 26712972
Drug: glycopyrrolate 0.2
RxNorm normalized name: glycopyrrolate 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate 0.2 mg (Group G, n = 31)